This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Institut Pasteur De Lille, National Institute of Health and Medical Research, Université De Lille. Active years: 2026.
Company Filing History:
1 out of 65 
1 out of 1,853 
1 out of 65 
Years Active: 2026
Title: Pierre Sierocki: Innovator in ERAP Inhibitors
Introduction
Pierre Sierocki is a notable inventor based in Mouvaul, France. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit endoplasmic reticulum aminopeptidases (ERAP). His work has implications for treating various disorders, showcasing his innovative spirit and dedication to scientific advancement.
Latest Patents
Pierre Sierocki holds 1 patent related to ERAP inhibitors. The patent discloses novel compounds of formula (I) that are useful as inhibitors of ERAP, specifically targeting ERAP2. These compounds are particularly relevant for the therapeutic treatment or prophylaxis of proliferative disorders, autoinflammatory disorders, and autoimmune disorders.
Career Highlights
Throughout his career, Pierre has been associated with prestigious institutions such as Université de Lille and Institut Pasteur de Lille. His work at these institutions has allowed him to collaborate with leading researchers and contribute to significant advancements in his field.
Collaborations
Pierre has worked alongside notable colleagues, including Valentin Guillaume and Damien Bosc. Their collaborative efforts have furthered research in the area of ERAP inhibitors and related therapeutic applications.
Conclusion
Pierre Sierocki's innovative contributions to the field of biochemistry, particularly through his patent on ERAP inhibitors, highlight his role as a significant inventor. His work continues to influence the development of treatments for various disorders, underscoring the importance of innovation in science.